Brazil's health regulator has said that the death of a 16-year-old who had a first dose of the Pfizer (NYSE:PFE)/BioNTech (Nasdaq:BNTX) COVID-19 vaccine was due to a prior blood clot condition not related to the vaccine, Reuters news agency reported on Thursday.
According to Anvisa, the death was caused by an auto-immune disease suffered by the adolescent.
"It was a characteristic clinical picture of thrombotic thrombocytopenic purpura, an autoimmune disease," Anvisa stated.
Thrombotic thrombocytopenic purpura is a rare disorder that causes blood clots to form in small blood vessels throughout the body that can cause serious medical problems if they restrict blood flow to organs such as the brain, kidneys or heart.
The Pfizer COVID-19 vaccine is the only one approved for minors in Brazil.
Brazil's federal government sought last week to halt COVID-19 vaccinations for adolescents while the death was under investigation as a suspected adverse event.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Innovent Biologics announces CFO transition
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial